Buckland Matthew, Ali Roshanara, Bothamley Graham, Lammas David, Doffinger Rainer, Longhurst Hilary
Barts and the London NHS Trust, Immunology, 214, 80 Newark St, London E1 2ES, UK.
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.11.2008.1278. Epub 2009 Dec 1.
This case of a middle aged woman with IL-12p40 deficiency and recurrent Mycobacterium kansasii infection demonstrates that in vitro sensitivities do not reliably predict the clinical response of non-tuberculous mycobacteria (NTMB), and emphasises the need to exercise caution when reducing treatment intensity in patients with type 1 cytokine defects on the basis of in vitro minimum inhibitory concentration (MIC) data alone.
这位中年女性患有白细胞介素-12 p40缺乏症并反复感染堪萨斯分枝杆菌,该病例表明体外药敏试验不能可靠地预测非结核分枝杆菌(NTMB)的临床反应,并强调仅根据体外最低抑菌浓度(MIC)数据降低1型细胞因子缺陷患者的治疗强度时需谨慎行事。